Evidence map›Paper›PMID 42406012›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026

Alternative therapy against CTX-M broad spectrum β-lactamase resistance gene in Klebsiella pneumoniae infection: bee venom and bee venom-derived nanovesicle fraction.

Demet Celebi, Ozgur Celebi, Sumeyye Baser, Ali Taghizadehghalehjoughi, Bulent Dabanlıoglu, Mustafa Can Guler, Elif Aydın, Serkan Yıldırım

Abstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Demet CelebiFaculty of Veterinary Medicine, Department of Microbiology, Atatürk University, Erzurum, 25240, Turkey. celebiidil@atauni.edu.tr.ORCID http://orcid.org/0000-0002-2355-0561
Ozgur CelebiFaculty of Medicine, Department of Medical Microbiology, Atatürk University, Erzurum, 25240, Turkey.ORCID http://orcid.org/0000-0003-4578-9474
Sumeyye BaserFaculty of Pharmacy, Department of Pharmaceutical Microbiology, Erzincan Binali Yıldırım University, Erzincan, 24002, Turkey.ORCID http://orcid.org/0000-0003-2391-8191
Ali TaghizadehghalehjoughiDepartment of Medical Pharmacology, Faculty of Medicine, Bilecik Şeyh Edebali University, Bilecik, 11230, Turkey.ORCID http://orcid.org/0000-0002-3506-0324
Bulent DabanlıogluFaculty of Medicine, Department of Medical Microbiology, Erzincan Binali Yıldırım University, Erzincan, 24002, Turkey.ORCID http://orcid.org/0000-0002-6953-7266
Mustafa Can GulerFaculty of Medicine, Department of Physiology, Atatürk University, Erzurum, 25240, Turkey.ORCID http://orcid.org/0000-0001-8588-1035
Elif AydınFaculty of Medicine, Department of Medical Microbiology, Ağrı İbrahim Çeçen University, Ağrı, 04100, Turkey.ORCID http://orcid.org/0000-0003-0877-453X
Serkan YıldırımFaculty of Veterinary Medicine, Department of Pathology, Atatürk University, Erzurum, 25240, Turkey.ORCID http://orcid.org/0000-0003-2457-3367

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic resistance is one of the most important problems threatening global public health by complicating the treatment of infections worldwide. The increase in resistant microorganisms creates a serious economic and social burden on healthcare systems and increasingly limits treatment options. Conscious use of antibiotics, infection control measures and the development of alternative treatment strategies are vital to ensure sustainability in health. Klebsiella pneumoniae is the most common gram-negative bacterium among urinary tract infections. Treatment of infections has become difficult due to the resistance to beta-lactam antibiotics. Bee venom (BV) and nanovesicle fractions isolated from BV are bioactive compounds with antimicrobial and antibiofilm activity. The aim of this study was to determine the antimicrobial and antibiofilm effects of BVand bee venom-derived nanovesicle fractions against the nosocomial infection agent K. pneumoniae, and to evaluate CTX-M PCR band detection under the tested conditions. Minimum inhibitory concentration (MIC), antibiofilm activity, fractional inhibition concentrations (FIC), CTX-M PCR band detection, and viability rates in L929 cells were evaluated for both BVand the bee venom-derived nanovesicle fraction against K. pneumoniae. MIC value of nanovesicle fractions isolated from BVwas determined as 1.95 mg/L. In combination with piperacillin and tazobactam, a synergistic effect was detected with a value of 0.5. Antibiofilm activity was measured with the highest absorbance value of 0.163 and 0.094 for BV nanovesicle fractions. A detectable CTX-M PCR band was observed in the BVgroup at 0.5× MIC, whereas no detectable band was observed at both concentrations by day 4. In the bee venom-derived nanovesicle fraction group, no detectable CTX-M PCR band was observed at 2× MIC and 0.5× MIC under the tested conditions. In contrast, detectable CTX-M PCR bands were observed in the piperacillin-tazobactam group. It was reported that the combination groups decreased the viability rate in L929 cell lines. The bee venom-derived nanovesicle fraction showed antimicrobial, antibiofilm, and PCR-based detection findings under the tested conditions, supporting the need for further investigation in broader in vitro and in vivo models.

Indexed as

Anti-Bacterial AgentsBee Venomsbeta-LactamasesKlebsiella InfectionsKlebsiella pneumoniaeAnimalsBiofilmsCell LineHumansMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsBee Venomsbeta-LactamasesAntibacterial resistanceBee venomCell cultureKlebsiella pneumoniaeNanovesicle fraction

Identifiers

PMID42406012
PMCPMC13337971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.